Kiromic reports update from Phase I NSCLC treatment trial [Yahoo! Finance]
KIROMIC BIOPHARMA INC (KRBP)
Company Research
Source: Yahoo! Finance
Deltacel is an off-the-shelf Gamma Delta T-cell (GDT) therapy. The open-label trial is designed to assess the safety and tolerability of two intravenous infusions of Deltacel with four courses of low-dose, localised radiation over a ten-day period in stage 4 NSCLC patients who have failed to respond to standard therapies. The primary goal of the Deltacel-01 trial is to assess the safety of the treatment. Secondary endpoints include measuring the progression-free survival (PFS), objective response, overall survival, time to treatment response, time to progression and disease control rates. Data from five patients assessed for PFS showed a range from two to eight months, with an average of 4.8 months. Notably, no dose-limiting toxicities (DLTs) were reported in subjects who completed the full therapy course. One patient, however, was withdrawn from the trial due to an adverse event related to a pre-existing condition, which was not associated with Deltacel, and therefore co
Show less
Read more
Impact Snapshot
Event Time:
KRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRBP alerts
High impacting KIROMIC BIOPHARMA INC news events
Weekly update
A roundup of the hottest topics
KRBP
News
- Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialBusiness Wire
- Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous RecommendationBusiness Wire
- Kiromic BioPharma’s Deltacel Receives FDA Fast Track DesignationBusiness Wire
- Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial [Yahoo! Finance]Yahoo! Finance
- Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 TrialBusiness Wire
KRBP
Sec Filings
- 8/26/24 - Form 4
- 8/21/24 - Form 4
- 8/14/24 - Form 4
- KRBP's page on the SEC website